These findings suggest that metabolic reprogramming of macrophages with the use of metformin may repolarise tumour-associated macrophages towards an anti-M1-like phenotype that could then enhance CD8+ T-cell effector function and suppress the recruitment of regulatory T-cells. The gene discussed is CD8A; the disease is neoplasm.